Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 2528.

https://doi.org/10.1182/blood-2019-123338

Published: 2019

Journal Articles

Accumulation of Endogenous DNA Damage Sustain Malignant Progression and Increase Therapy Resistance in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Evangelos Terpos, MD PhD, Nikhil C. Munshi, MD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1788.

https://doi.org/10.1182/blood-2019-123502

Published: 2019

Journal Articles

Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan

Maria Gkotzamanidou, Evangelos Terpos, Nikhil C Munshi, MD, Vassilis L. Souliotis, Meletios A Dimopoulos

Blood (2016) 128 (22): 4437.

https://doi.org/10.1182/blood.V128.22.4437.4437

Published: 2016

Journal Articles

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7

Maria Gkotzamanidou, Evangelos Terpos, Christina Bamia, Nikhil C. Munshi, Meletios A. Dimopoulos, Vassilis L. Souliotis

Blood (2016) 128 (9): 1214–1225.

https://doi.org/10.1182/blood-2016-01-691618

Published: 2016

Includes: Supplemental data

Journal Articles

The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan

Maria Gkotzamanidou, Evangelos Terpos, Nikhil C. Munshi, MD, Vassilis L. Souliotis, Meletios A. Dimopoulos

Blood (2015) 126 (23): 3628.

https://doi.org/10.1182/blood.V126.23.3628.3628

Published: 2015

Journal Articles

The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors

Maria Gkotzamanidou, Evangelos Terpos, Nikhil C. Munshi, MD, Vassilis L. Souliotis, Meletios A. Dimopoulos

Blood (2015) 126 (23): 4177.

https://doi.org/10.1182/blood.V126.23.4177.4177

Published: 2015

Journal Articles

Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Masood Shammas, PhD, Vassilis L. Souliotis, Weihua Song, MD, Jagannath Pal, MBBS, PhD, Puru Nanjappa, MS, Naim Rashid, PhD, Kenneth C. Anderson, MD, Meletios A. Dimopoulos, MD, James Bradner, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3398.

https://doi.org/10.1182/blood.V124.21.3398.3398

Published: 2014

Journal Articles

Spontaneous DNA Damage and Aberrant Epigenome In Multiple Myeloma Constitute The Path To Disease Genomic Instability

Maria Gkotzamanidou, MD, PhD, Masood A. Shammas, Vassilis L. Souliotis, Jagannath Pal, MD, Jun Qi, Ph.D., Andrew Brown, James E Bradner, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 4884.

https://doi.org/10.1182/blood.V122.21.4884.4884

Published: 2013

Journal Articles

Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy

Maria Gkotzamanidou, Masood A. Shammas, Evangelos Terpos, Enrique M. Ocio, Jesús F. San Miguel, MD, PhD, Nikhil C. Munshi, MD, Meletios A. Dimopoulos, MD, Vassilis L. Souliotis

Blood (2013) 122 (21): 3723.

https://doi.org/10.1182/blood.V122.21.3723.3723

Published: 2013

Journal Articles

Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma

Maria Gkotzamanidou, Evangelos Terpos, Petros P. Sfikakis, Meletios Athanasios Dimopoulos, MD, Vassilis L. Souliotis

Blood (2011) 118 (21): 299.

https://doi.org/10.1182/blood.V118.21.299.299

Published: 2011

Journal Articles

Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma

Vassilis L. Souliotis, Maria Gkotzamanidou, Petros P. Sfikakis, Evangelos Terpos, Soterios A. Kyrtopoulos, Meletios A. Dimopoulos

Blood (2010) 116 (21): 2974.

https://doi.org/10.1182/blood.V116.21.2974.2974

Published: 2010

Journal Articles

Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma

Vassilis L. Souliotis, Maria Gkotzamanidou, Petros P. Sfikakis, Evangelos Terpos, Christos Papadimitriou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikitas Nikitas, Efstathios Kastritis, Soterios A. Kyrtopoulos, Meletios A. Dimopoulos

Blood (2010) 116 (21): 2976.

https://doi.org/10.1182/blood.V116.21.2976.2976

Published: 2010

Journal Articles

Alterations in the Epigenetic Network Controlling Transcription Activity, Chromatin Structure and Region-Specific Repair of Different Genomic Loci Predicts Clinical Outcome in Multiple Myeloma.

Hara G. Episkopou, Soterios A. Kyrtopoulos, Petros P. Sfikakis, Maria Fousteri, Evangelos Terpos, Leon H. Mullenders, Vassilis L. Souliotis, Meletios A. Dimopoulos

Blood (2009) 114 (22): 122.

https://doi.org/10.1182/blood.V114.22.122.122

Published: 2009

Journal Articles

A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma.

Meletios A. Dimopoulos, Christine Liakos, Hara G. Episkopou, Dimitra T. Stefanou, Soterios A. Kyrtopoulos, Petros P. Sfikakis, Evangelos Terpos, Aristotelis Bamias, Vassilis L. Souliotis

Blood (2009) 114 (22): 1879.

https://doi.org/10.1182/blood.V114.22.1879.1879

Published: 2009

Journal Articles

Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.

Meletios A. Dimopoulos, MD, Vassilis L. Souliotis, PhD, Athanasios Anagnostopoulos, M.D., Christina Bamia, PhD, Anastasia Pouli, M.D., Ioannis Baltadakis, M.D., Evangelos Terpos, M.D., Soterios A. Kyrtopoulos, PhD, Petros P. Sfikakis, M.D.

Blood (2006) 108 (11): 60.

https://doi.org/10.1182/blood.V108.11.60.60

Published: 2006

NARROW

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Accumulation of Endogenous DNA Damage Sustain Malignant Progression and Increase Therapy Resistance in Multiple Myeloma

Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7

The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan

The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors

Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma

Spontaneous DNA Damage and Aberrant Epigenome In Multiple Myeloma Constitute The Path To Disease Genomic Instability

Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy

Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma

Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma

Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma

Alterations in the Epigenetic Network Controlling Transcription Activity, Chromatin Structure and Region-Specific Repair of Different Genomic Loci Predicts Clinical Outcome in Multiple Myeloma.

A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma.

Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only